Octave

Katie Fischer Ascends to Partnership, Amplifying Daversa Partners' Leadership Team

Retrieved on: 
Tuesday, December 19, 2023
Technology, Human Resources, Venture Capital, Security, Fintech, Consulting, Thought Leadership, Professional Services, Software, Small Business, Culture, Partnership, Partner, Health, Multimedia, Octave, B2B, Engineering, Growth, Climate, Management

Daversa Partners , the technology industry’s premier executive search firm that builds the leadership teams for growth and venture-backed companies, announced today Katie Fischer as the firm’s newest Partner.

Key Points: 
  • Daversa Partners , the technology industry’s premier executive search firm that builds the leadership teams for growth and venture-backed companies, announced today Katie Fischer as the firm’s newest Partner.
  • With a track record spanning over a decade in executive recruiting, Fischer's ascent to the senior leadership team marks a significant milestone for the firm.
  • View the full release here: https://www.businesswire.com/news/home/20231219257399/en/
    Katie Fischer joins firm's partnership, expanding Daversa Partners' leadership team.
  • Reflecting on her tenure at Daversa Partners, Katie Fischer stated, "My journey began twelve years ago, and it's been an exhilarating experience to contribute to the evolution of this firm."

Octave® Bioscience, Inc. Announces Chairman of the Board, CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for its Precision Care Solution

Retrieved on: 
Tuesday, December 5, 2023
Research, Mental Health, Technology, Neurology, Other Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Blue Shield, Mentorship, Multiple sclerosis, Michael J. Critelli, Growth, McKesson Corporation, Quality of life, Management, Alivecor, Octave

Simultaneously, the company announced that industry leader, Doug Biehn, has been named President and CEO, effective immediately.

Key Points: 
  • Simultaneously, the company announced that industry leader, Doug Biehn, has been named President and CEO, effective immediately.
  • “Today, we are a true commercial company, which calls for new strategies, skills, and leadership.
  • Additionally, he is a Board Advisor for a number of early-stage digital health companies and mentors graduate students in the Stanford Business School Lean Launchpad program.
  • Fox Foundation to develop a custom protein biomarker panel that will measure Parkinson’s disease activity and progression in the clinic.

Octave® Bioscience, Inc. Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate Multi-Analyte Protein Biomarker Test for Parkinson’s Disease Assessments

Retrieved on: 
Wednesday, November 15, 2023
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Biomarker, Research, Parkinson's disease, Disease, Sclerosis, Marker beacon, MJFF, Octave, Medical Affairs Bureau, Multiple sclerosis, Neurodegenerative disease, Doctor of Philosophy, Pharmaceutical industry, Medical imaging

A multiplexed biomarker assay panel for Parkinson’s could further accelerate research and development of new therapies and provide a tool for better monitoring and management of the disease.

Key Points: 
  • A multiplexed biomarker assay panel for Parkinson’s could further accelerate research and development of new therapies and provide a tool for better monitoring and management of the disease.
  • Octave was selected to receive this grant as a result of the company’s track record in biomarker research and its successful commercialization of a multiplexed custom biomarker assay panel for multiple sclerosis.
  • Using PPMI, MJFF recently announced groundbreaking research that it had validated a biological diagnostic test to objectively and reliably detect alpha-synuclein protein, a hallmark of Parkinson’s disease.
  • “Our goal is to create a powerful biomarker tool that addresses a variety of applications ranging from disease activity and progression, disease staging and subtyping, as well as disease modifying treatment development and monitoring.

Octave® Bioscience, Inc. Presents Data Highlighting Application and Impact of its Precision Care Solution at MSMilan2023

Retrieved on: 
Wednesday, October 11, 2023
Research, Technology, Neurology, Other Technology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Partnership, HIV disease progression rates, Medicine, Biomarker, MS, KOL, Proteomics, Disease, Multiple sclerosis, MRI, Poster, Medical device, Medical imaging, Octave

Octave® Bioscience , Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced new data shared in nine poster presentations at MSMilan2023 , the 9th Joint ECTRIMS-ACTRIMS Meeting.

Key Points: 
  • Octave® Bioscience , Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, announced new data shared in nine poster presentations at MSMilan2023 , the 9th Joint ECTRIMS-ACTRIMS Meeting.
  • The data, presented in partnership with several KOL research partners, demonstrates a wide range of findings deploying Octave’s Precision Care Solution, revealing important insights about disease behavior in both research and real-world settings - bringing precision medicine to the forefront.
  • “Octave's mission is to provide tools that accurately and objectively measure disease activity, progression, and severity, and enable better management of complex and high-cost neurodegenerative diseases like multiple sclerosis,” said William Hagstrom, Octave’s Founder and Chief Executive Officer.
  • Octave presented data on its clinically-validated multivariate biomarker blood test, the first of its kind and designed specifically for MS, in multiple posters at MSMilian2023.

Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management

Retrieved on: 
Wednesday, September 6, 2023
Science, Neurology, Radiology, Biotechnology, Research, Health, Clinical Trials, Other Health, Octave, Depression, Anxiety, Neurodegenerative disease, Oklahoma Medical Research Foundation, BIIB, Multiple sclerosis, Doctor of Philosophy, MS, Organization, MRI, Neuroscience, Rocky Mountains, MD, Patient, Practitioner, OMRF, Orlando Health, FAAN, Medical imaging, Nursing, Biogen

The study will utilize the Octave® Precision Care Solution (Octave®Solution) to evaluate 150 patients with MS at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s (OMRF) MS Center of Excellence, and Orlando Health MS Comprehensive Care Center.

Key Points: 
  • The study will utilize the Octave® Precision Care Solution (Octave®Solution) to evaluate 150 patients with MS at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s (OMRF) MS Center of Excellence, and Orlando Health MS Comprehensive Care Center.
  • Octave’s Solution provides neurologists and their patients with quantitative, objective metrics to facilitate informed care and shared decision making to provide a more personalized MS care approach.
  • The study is expected to be conducted for 12 months following patient enrollment.
  • “For those of us who have been researching and treating MS for decades, it is a promising step forward for us and, most importantly, for our patients.”

 Octave® Bioscience, Inc. Announces Publication of Clinical Validation Study Results of its Novel, Multivariate Multiple Sclerosis Disease Activity (MSDA) Blood Test

Retrieved on: 
Wednesday, August 30, 2023
Health, Neurology, Clinical Trials, Research, Science, Biotechnology, MS Communications, Octave, Mass General Brigham, Immunomodulation, Prognosis, Biomarker, Multiple sclerosis, MS, Immunology, MRI, Patient, Machine learning, Mass, Diagnosis, Ecosystem, Disease, Medical device, Medical imaging, MD

The ongoing management of disease activity – the occurrence of new neurological symptoms and the rate of relapses – is a central theme of improving outcomes.

Key Points: 
  • The ongoing management of disease activity – the occurrence of new neurological symptoms and the rate of relapses – is a central theme of improving outcomes.
  • Historically, however, there have been no dynamic, quantitative tools to measure disease activity over time.
  • The test can be used throughout the course of a patient’s disease to enable more informed, actionable clinical decisions that will help with better disease management.
  • “We are encouraged that these results validate the performance of the Octave MSDA Test and demonstrate its ability to quantitatively and objectively measure disease activity of patients with MS.

Susan G. Komen® To Host Race For The Cure in New York City This Fall

Retrieved on: 
Monday, August 21, 2023
The Norfolk & Dedham Group, Walkers, Amanda, Cure, The Bountiful Company, PepsiCo, WCBS-TV, Patient, Susan, ShopRite, Breast cancer, Disease, Dietary supplement, Octave, New York Post

NEW YORK, Aug. 21, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, today announced it will host a Race for the Cure this fall.

Key Points: 
  • NEW YORK, Aug. 21, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, today announced it will host a Race for the Cure this fall.
  • The Greater New York City Race for the Cure will take place on Sunday, Sept. 10, 2023.
  • This year's Greater New York City Race for the Cure is made possible by the following sponsors: PepsiCo, Nature's Bounty, Pfizer Oncology, ZENITH, Your Local Ford Stores, ShopRite, Kohn Pederson Fox Associates, Piper Sandler & Co., Octave, The Dedham Group, CBS New York and New York Post.
  • Natalie Duddridge, award-winning journalist and CBS New York reporter, is serving as Race Day Emcee.

FOUNDER OF OCTAVE INSTITUTE, CHAVALIT FREDERICK TSAO MAKES A COLLABORATIVE CONTRIBUTION TOWARDS HALOGEN FOUNDATION

Retrieved on: 
Thursday, August 17, 2023
Well, Partnership, Octave, United Nations Environment Programme Finance Initiative, Halogen Foundation, United Nations, Nature, Happiness, Ethics, Knowledge, Ecosystem, Consciousness, Pharmaceutical industry, Management, Retail, Nursing, Halogen, Life

SINGAPORE, Aug. 17, 2023 /PRNewswire/ -- To drive change and co-create a new era of oneness and holistic well-being, business steward Mr Chavalit Frederick Tsao, Founder of Octave Institute ("Octave") and Chairman of IMC Pan Asia Alliance Group ("IMCPAA"), collaborates with Halogen Foundation Singapore ("Halogen"), a not-for-profit Institution to co-creating the future of youth in Singapore. Octave presented a collaborative contribution of $250,000 to Halogen today during The Halogen Ball hosted by Halogen, and graced by Guest-of-Honour, Mr Tharman Shanmugaratnam. Octave is also the presenting sponsor of this event. This marks the beginning of a relationship between Octave and Halogen, to bringing awareness of our youth to humanity's synchronicity with nature and the flourishing of Life through collaborations between Octave Institute and Halogen Foundation.

Key Points: 
  • Fourth generation business steward and founder of Octave Institute, Chavalit Frederick Tsao collaborates with Halogen Foundation to partner in co-creating a cross-generational education system beyond schooling for youth, towards the shared future and destiny for humanity.
  • Octave presented a collaborative contribution of $250,000 to Halogen today during The Halogen Ball hosted by Halogen, and graced by Guest-of-Honour, Mr Tharman Shanmugaratnam.
  • This marks the beginning of a relationship between Octave and Halogen, to bringing awareness of our youth to humanity's synchronicity with nature and the flourishing of Life through collaborations between Octave Institute and Halogen Foundation.
  • Founded by Mr Tsao, Octave is a school of life and management, with focus on business reforms and leadership transformation.

FOUNDER OF OCTAVE INSTITUTE, CHAVALIT FREDERICK TSAO MAKES A COLLABORATIVE CONTRIBUTION TOWARDS HALOGEN FOUNDATION

Retrieved on: 
Thursday, August 17, 2023
Well, Partnership, Octave, Multimedia, United Nations Environment Programme Finance Initiative, Halogen Foundation, United Nations, Nature, Happiness, Ethics, Knowledge, Ecosystem, Consciousness, Pharmaceutical industry, Management, Retail, Nursing, Halogen, Life

SINGAPORE, Aug. 17, 2023 /PRNewswire/ -- To drive change and co-create a new era of oneness and holistic well-being, business steward Mr Chavalit Frederick Tsao, Founder of Octave Institute ("Octave") and Chairman of IMC Pan Asia Alliance Group ("IMCPAA"), collaborates with Halogen Foundation Singapore ("Halogen"), a not-for-profit Institution to co-creating the future of youth in Singapore. Octave presented a collaborative contribution of $250,000 to Halogen today during The Halogen Ball hosted by Halogen, and graced by Guest-of-Honour, Mr Tharman Shanmugaratnam. Octave is also the presenting sponsor of this event. This marks the beginning of a relationship between Octave and Halogen, to bringing awareness of our youth to humanity's synchronicity with nature and the flourishing of Life through collaborations between Octave Institute and Halogen Foundation.

Key Points: 
  • Fourth generation business steward and founder of Octave Institute, Chavalit Frederick Tsao collaborates with Halogen Foundation to partner in co-creating a cross-generational education system beyond schooling for youth, towards the shared future and destiny for humanity.
  • Octave presented a collaborative contribution of $250,000 to Halogen today during The Halogen Ball hosted by Halogen, and graced by Guest-of-Honour, Mr Tharman Shanmugaratnam.
  • This marks the beginning of a relationship between Octave and Halogen, to bringing awareness of our youth to humanity's synchronicity with nature and the flourishing of Life through collaborations between Octave Institute and Halogen Foundation.
  • Founded by Mr Tsao, Octave is a school of life and management, with focus on business reforms and leadership transformation.

Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases

Retrieved on: 
Wednesday, July 26, 2023
Partnership, Octave, Approximation error, Multiple sclerosis, MS, Alzheimer's disease, Parkinson's disease, HIV disease progression rates, Patient, Physician, Medicine, Health, Disease, Pharmaceutical industry

LONDON, July 26, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures , has invested in Octave Bioscience , the developer of a first-of-its-kind platform to accurately and objectively measure and help manage complex and high-cost neurodegenerative diseases, starting with multiple sclerosis (MS).

Key Points: 
  • LONDON, July 26, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures , has invested in Octave Bioscience , the developer of a first-of-its-kind platform to accurately and objectively measure and help manage complex and high-cost neurodegenerative diseases, starting with multiple sclerosis (MS).
  • "There is an immense unmet need within the MS space with outdated diagnostic tools, a lack of technological advancement, and limited support in addressing neurodegenerative diseases.
  • "By offering an end-to-end solution which optimizes and personalizes care, Octave is revolutionising the way MS is treated and managed.
  • Octave Bioscience will use the proceeds to support their commercialization efforts in MS and to explore expansion opportunities into other neurodegenerative diseases such as Parkinson's and Alzheimer's.